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High fluoroquinolone MIC is 
associated with fluoroquinolone treatment 
failure in urinary tract infections caused 
by fluoroquinolone susceptible Escherichia coli
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Abstract 
Background: Suboptimal clinical response to fluoroquinolone (FQ) therapy has been clearly documented in patients 
with Salmonella typhi infection with reduced FQ susceptibility. However, the clinical impact of reduced FQ suscepti-
bility on other infections including E. coli urinary tract infections (UTIs) has never been evaluated.
Methods: We conducted a retrospective cohort study of female patients with fluoroquinolone susceptible E. coli 
(FQSEC) UTIs who received FQ therapy at outpatient services within University of Pennsylvania Health System, Phila-
delphia. Exposed patients were those with high MIC-FQSEC UTIs (the levofloxacin MIC > 0.12 but ≤ 2 mg/L) while 
unexposed patients were those with low MIC-FQSEC UTIs (the levofloxacin MIC ≤ 0.12 mg/L). The primary treatment 
outcome was treatment failure within 10 weeks after initiation of FQ therapy.
Results: From May 2008 to April 2011, we enrolled 29 exposed patients and 246 unexposed patients. Two patients 
in each group experienced treatment failure; exposed vs. unexposed (6.9 vs. 0.8%; p = 0.06). Risk difference and risk 
ratio (RR) for treatment failure were 0.06 [95% CI −0.03–0.15; exact-p = 0.06] and 8.48 [95% CI 1.24–57.97; exact-
p = 0.06], respectively. After adjusting for underlying cerebrovascular disease, the RR was 7.12 (95% CI 1.20–42.10; 
MH-p = 0.04).
Conclusion: Our study demonstrated the negative impact of reduced FQ susceptibility on the treatment response to 
FQ therapy in FQSEC UTIs. This negative impact may be more intensified in other serious infections. Future studies in 
other clinical situations should be conducted to fill the gap of knowledge.
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Background
Fluoroquinolone (FQ) susceptibility is traditionally 
reported as susceptible, intermediate, or resistant [1]. 
Some investigators further categorized the fluoroqui-
nolone susceptible E. coli (FQSEC) isolates into two 
additional subgroups, based on the MIC cutoff value; (1) 
Fully susceptible strain or low MIC-FQSEC group (the 
MIC level against levofloxacin ≤ 0.12 mcg/mL); and (2) 
Reduced susceptible strain or High-MIC FQSEC group 
(levofloxacin MIC  >  0.12 but  ≤  2  mg/L) [2, 3]. These 
reduced susceptible strains potentially result in devel-
opment of full resistance to FQ and may lead to delayed 
response to FQ therapy [4].
Negative impact of high MIC-FQ susceptibility on 
treatment outcomes has been previously documented in 
several studies [5, 6]. The previous study from Vietnam 
revealed that high MIC-FQ susceptibility was associated 
with treatment failure in patients with enteric fever who 
received ofloxacin therapy [6]. However, another recent 
study from Vietnam did not find any association between 
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poorer outcome and reduced FQ susceptibility among 
pediatric patients with Shigella infections [7]. Further-
more, the impact of high MIC-FQ susceptibility on clini-
cal outcomes among patients with infection caused by E. 
coli has never been thoroughly investigated.
Given these considerations, we conducted a retrospec-
tive cohort study aiming to determine the clinical impact 
of high MIC-FQ susceptibility on FQ treatment response 
among female patients with fluoroquinolone susceptible 




We conducted a retrospective cohort study of female sub-
jects with FQSEC UTIs who received FQ therapy at out-
patient practices within University of Pennsylvania Health 
System (UPHS). Our study population was the subset of 
an ambulatory FQSEC UTI cohort at UPHS (n = 2001). 
A detailed description of the UPHS cohort has been pub-
lished elsewhere [8]. The study was approved by the Uni-
versity of Pennsylvania Institutional Review Board.
Inclusion criteria and study definition
We enrolled female adults (age ≥ 18 years) who met the 
study definition for FQSEC UTIs and received any FQ 
antibiotic as the first antibiotic regimen for treatment of 
UTI within 72 h before or after obtaining an index urine 
culture. Exposed patients were those with high MIC 
FQSEC-UTIs and unexposed patients were those with 
low MIC-FQSEC UTIs.
Either upper or lower UTIs were eligible for the study. 
If an eligible patient had more than one episode of 
UTI during the study period, only the first episode was 
included. Patients who had a UTI episode within 30 days 
prior to the beginning of the study were also excluded. 
All forms of FQ antibiotic including oral form, intrave-
nous form (outpatient antimicrobial therapy) and IV-to-
PO switching were eligible. The index date was the first 
date of FQ therapy.
Study definitions of UTIs are shown in Table 1. For the 
treatment outcome, a given patient was documented as 
having treatment failure if at least one of the following cri-
teria were met within 10 weeks after initiation of FQ ther-
apy; (1) a second course of antibiotic therapy for UTI was 
prescribed; (2) any evidence of persistent or recurrent E. 
coli bacteriuria (At least  103 cfu/mL of E. coli isolate).
Microbiological test
Microbiological tests were routinely processed at the 
Hospital of University of Pennsylvania microbiology 
laboratory (HUP MicroLab). All tests were processed by 
the Vitek-2 system (bioMerieux Inc.), according to the 
performance standards for antimicrobial susceptibility 
testing established by Clinical and Laboratory Standards 
Institute (CLSI) [1]. The Vitek card used in our study pro-
vides a resulting range of seven MIC doubling dilution 
(≤ 0.12, 0.25, 0.5, 1, 2, 4 and ≥ 8).
An E. coli isolate with the levofloxacin MIC ≤ 2 mg/L 
was considered FQSEC. The low MIC isolates were those 
FQSEC with the levofloxacin MIC ≤ 0.12 mg/L while the 
high MIC isolates were those FQSEC isolates with the 
levofloxacin MIC > 0.12 but ≤ 2 mg/L.
Data collection
Baseline characteristics were obtained via our inte-
grated electronic clinical database called Penn Data 
Store (including outpatient and inpatient electronic 
medical records, laboratory database and billing data-
base). Microbiological results were obtained via the HUP 
MicroLab laboratory information system. Chart-review 
was performed by the principal investigator to determine 
treatment outcomes.
Statistical analysis
Categorical variables were analyzed using the Chi square 
or Fisher’s exact test and continuous variables were com-
pared using the student’s t or Mann–Whitney U test, 
depending on the sample distribution. Mantel–Haenszel 
method was used for adjusting of single potential con-
founder. A two-tailed p value of < 0.05 was considered sta-
tistically significant. All calculations were performed using 
the STATA version 12.0 (Stata Corp, College Station TX).
Results
During a 3-year study period (May 1, 2008–April 30, 
2011), a total of 279 eligible patients were identified. 
However, only 275 study patients had available medi-
cal record data for review. Of these 275 patients, there 
Table 1 Study definition of urinary tract infections (UTIs)
To be diagnosed of UTI, an eligible subject must meet both crite-
rion 1 and criterion 2
Criterion 1 Having a positive urine culture ≥ 105 cfu/mL, with no more 
than two species of microorganism
Criterion 2 At least one of the following
 ICD-9 code of signs and symptoms of UTIs
 Dipstick test positive for leukocyte esterase and/or nitrate
 Pyuria (≥ 10 white blood cells (wbc)/mm3 or ≥ 3 wbc/
high power field of unspun urine)
 Physician diagnosis of a urinary tract infection (ICD-9 
code)
  599.0 Urinary tract infection, site not specified
  590.x Infection of kidney
  595.0 Acute cystitis
  597.x Urethritis, not sexually transmitted diseases
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were 29 patients in the high MIC-FQSEC group and 
246 patients in the low MIC-FQSEC group. Median age 
(range) of the high MIC-FQSEC group and the low MIC-
FQSEC group were 64 [18–89] years and 55 [18–99] 
years, respectively. Four of patients in the high MIC-
FQSEC group and four patients in the low MIC-FQSEC 
group were treated with intravenous fluoroquinolone 
for a few days before switching to the oral form. Base-
line characteristics between the high MIC-FQSEC and 
the low MIC-FQSEC groups are comparable as shown in 
Table 2.
Two patients in the high MIC-FQSEC group and two 
patients in the low MIC-FQSEC group experienced treat-
ment failure (6.9 vs. 0.8%; p = 0.06). All four failure cases 
had persistent signs or symptoms of UTIs and subse-
quently required a second course of antibiotic therapy. 
Details of treatment failure are available as shown in 
Table  3. Of note, only one of the four had a follow-up 
urine culture and that given culture did not meet crite-
ria for significant bacteriuria. Risk difference (RD) and 
risk ratio (RR) for treatment failure comparing high vs. 
low MIC groups were 0.06 [95% CI −0.03–0.15; exact-
p = 0.06] and 8.48 [95% CI 1.24–57.97; exact-p = 0.06], 
respectively.
Baseline characteristics of patients who experienced 
(n  =  4) and who did not experience treatment failure 
(n = 271) are shown in Table 4. In the bivariable analy-
sis, treatment failure was significantly associated with 
race (p = 0.04) and underlying cerebrovascular diseases 
(p = 0.01). After adjusting for having underlying cerebro-
vascular disease, we found that patients with high MIC-
FQSEC UTIs were approximately seven times more likely 
to experience treatment failure after receiving FQ ther-
apy comparing with those with low MIC-FQSEC UTIs 
(RR  =  7.12; 95% CI 1.20–42.10]; MH-p value  =  0.04). 
Race was not found to be a significant confounding 
factor.
Discussion
Based on data from our study, the FQ treatment failure 
rate was only 0.8% in the low MIC group and 6.9% in 
the high MIC group. Although the failure rate was not 
high, the patients with high MIC-FQSEC UTIs was seven 
times more likely to experience treatment failure after 
adjusting for underlying cerebrovascular disease.
Based on this finding, FQ therapy should be care-
fully given to only FQSEC-UTI cases with a low risk for 
reduced FQ susceptibility. Use a higher dose of FQ may 
resolve this problem. However, the US Food and Drug 
Administration has recently advised to avoid FQ ther-
apy for mild conditions including uncomplicated UTIs 
because of its serious side effects. FQs should be reserved 
for only those who do not have alternative treatment 
options.
We believe that our study has several strengths. First, 
our study definition to identify ambulatory FQSEC UTIs 
has shown promising discrimination ability in our pilot 
study (87.8% sensitivity and 85.7% specificity). For this 
reason, only patients with true UTIs were enrolled into 
our study. Although the negative impact of high MIC-
FQ susceptibility on treatment response to FQ therapy 
has been previously documented in infections caused 
by Salmonella enteric serovar Typhi (S. typhi) [5, 6], our 
study was the first study exploring this issue in E.coli 
uropathogen.
Table 2 Baseline characteristics of patients in the low MIC 
group vs. the high MIC group






N % N %
Median age [range] 64 [18–89] 55 [18–99] 0.35*
 Race
  White 15 51.7 89 36.2 0.14*
  Black 11 37.9 141 57.3
  Asian 1 3.5 4 1.6
  Other/unknown 2 6.9 12 4.9
 Co-morbidity
  Median Charlson 
index [range]
0 [0–2] 0 [0–2] 0.44*
  Having at least one 
Charlson conditions
8 27.6 54 22.0 0.49
  Acute myocardial 
infarction
1 3.5 4 1.6 0.43*
  Congestive heart 
failure
3 10.3 8 3.3 0.10*
  Peripheral vascular 
disease
0 0.0 6 2.4 0.99*
  Cerebrovascular 
disease
2 6.9 12 4.9 0.65*
  Dementia 0 0.0 3 1.2 0.99*
  COPD 1 3.5 14 5.7 0.99*
  Rheumatoid disease 0 0.0 1 0.4 0.99*
  Peptic ulcer 0 0.0 1 0.4 0.99*
  Mild liver disease 1 3.5 0 0.0 0.11*
  Moderate/severe liver 
disease
0 0.0 0 0.0 –
  Diabetes 1 3.5 3 1.2 0.36*
  Hemiplegia or para-
plegia
0 0.0 1 0.4 0.99*
  Renal disease 2 6.9 6 2.4 0.20*
  Cancer 1 3.5 12 4.9 0.99*
  Metastatic cancer 0 0.0 7 2.9 0.99*
  AIDS 0 0.0 0 0.0 –
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Our study had several potential limitations. Since the 
patients with high MIC-FQSEC UTIs may be sicker than 
patients with low MIC-FQSEC UTIs, this may result in 
a higher rate of treatment failure among the high MIC 
group. Due to a small sample size, we may not be able to 
adjust for all potential confounders. Second, it is still pos-
sible that we may overlook some failure event, although 
we used the specifically designed criteria to detect treat-
ment failure. Since patients who experience treatment 
failure may seek a second opinion from other medical 
providers, treatment failure could be underestimated. To 
address this issue, we performed chart-review to iden-
tify documented off-network visit and treatment failure. 
Of these 275 study patients, there was only one docu-
mented off-network visit occurred within 3 months after 
the index date. This off-network visit occurred in the low 
MIC group (0.4%, 1/275) and it was not correlated to 
the UTI episode. Therefore, information bias due to off-
network visits should be very minimal. Another poten-
tial limitation is generalizability. This study primarily 
focused on female patients with non-recurrent ambula-
tory FQSEC-UTIs, therefore, the results of this study 
may not be applicable to recurrent UTIs, UTIs caused by 
other pathogens, other sites of infection as well as UTIs 
in the non-ambulatory setting. The last but very impor-
tant limitation is a very low number of treatment failure 
(n = 4). The significant difference identified in this study 
may happen by chance.
Conclusion
Based on the study results, high MIC-FQ susceptibil-
ity (or reduced FQ susceptibility) was associated with 
higher rates of treatment failure among female patients 
with ambulatory FQSEC UTIs after adjusting for under-
lying cerebrovascular disease. However, there were only 
few cases with treatment failure identified in this study. 
Future studies with a larger sample size are in need to 
confirm these findings.
Furthermore, the US Food and Drug Administra-
tion has recently advised to avoid FQ therapy for mild 
Table 4 Baseline characteristics of patient in the treatment failure group vs. the no treatment failure group







N % N %
Median age [range] 65.5 [45–87] 57.0 [18–99] 0.37
 Race
  White 3 75.0 101 37.3 0.04
  Black 0 0.0 152 56.1
  Asian 0 0.0 5 1.9
  Other/unknown 1 25.0 13 4.8
 Co-morbidity
  Median Charlson index [range] 0 [0–2] 0 [0–2] 0.19
  Having at least one Charlson conditions 2 50.0 60 22.1 0.22
  Acute myocardial infarction 1 25.0 4 1.5 0.07
  Congestive heart failure 0 0.0 11 4.1 0.99
  Peripheral vascular disease 0 0.0 6 2.2 0.99
  Cerebrovascular disease 2 50.0 12 4.4 0.01
  Dementia 0 0 3 1.1 0.99
  COPD 0 0 15 5.5 0.99
  Rheumatoid disease 0 0 1 0.4 0.99
  Peptic ulcer 0 0 1 0.4 0.99
  Mild liver disease 0 0 1 0.4 0.99
  Moderate/severe liver disease 0 0 0 0 –
  Diabetes 0 0 4 1.5 0.99
  Hemiplegia or paraplegia 0 0 1 0.4 0.99
  Renal disease 0 0 8 3.0 0.99
  Cancer 0 0 13 4.8 0.99
  Metastatic cancer 0 0 7 2.5 0.99
  AIDS 0 0 0 0 –
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conditions including uncomplicated UTIs because of 
its serious side effects. FQs should be reserved for only 
those who do not have alternative treatment options.
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